KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Leases (2017 - 2025)

Alnylam Pharmaceuticals' Leases history spans 14 years, with the latest figure at $194.9 million for Q4 2025.

  • For Q4 2025, Leases rose 1.97% year-over-year to $194.9 million; the TTM value through Dec 2025 reached $194.9 million, up 1.97%, while the annual FY2025 figure was $194.9 million, 1.97% up from the prior year.
  • Leases reached $194.9 million in Q4 2025 per ALNY's latest filing, up from $191.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $238.1 million in Q2 2021 to a low of $191.1 million in Q4 2024.
  • Average Leases over 5 years is $210.7 million, with a median of $206.1 million recorded in 2023.
  • Peak YoY movement for Leases: rose 7.2% in 2021, then dropped 9.11% in 2024.
  • A 5-year view of Leases shows it stood at $231.7 million in 2021, then fell by 7.14% to $215.1 million in 2022, then dropped by 7.16% to $199.7 million in 2023, then decreased by 4.3% to $191.1 million in 2024, then grew by 1.97% to $194.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Leases are $194.9 million (Q4 2025), $191.4 million (Q3 2025), and $192.4 million (Q2 2025).